PE20091345A1 - Arilindenopirimidinas como antagonistas del receptor a2a de adenosina - Google Patents

Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Info

Publication number
PE20091345A1
PE20091345A1 PE2008001825A PE2008001825A PE20091345A1 PE 20091345 A1 PE20091345 A1 PE 20091345A1 PE 2008001825 A PE2008001825 A PE 2008001825A PE 2008001825 A PE2008001825 A PE 2008001825A PE 20091345 A1 PE20091345 A1 PE 20091345A1
Authority
PE
Peru
Prior art keywords
disease
adenosine
antagonists
arylindenopyrimidines
receptor
Prior art date
Application number
PE2008001825A
Other languages
English (en)
Inventor
Brian C Shook
Paul F Jackson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20091345A1 publication Critical patent/PE20091345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULAS A, B O C, SOLVATOS, HIDRATOS, TAUTOMEROS Y SALES FARMACEUTICAS ACEPTABLES DE ESTOS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE ADENOSINA A2A, SIENDO UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DE PARKINSON, MAL DE HUNTINGTON, ATROFIA SISTEMICA MULTIPLE, DEGENERACION CORTICOBASAL, ENFERMEDAD DE ALZHEIMER Y DEMENCIA SENIL, ENTRE OTROS
PE2008001825A 2007-10-25 2008-10-24 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina PE20091345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
PE20091345A1 true PE20091345A1 (es) 2009-09-24

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001825A PE20091345A1 (es) 2007-10-25 2008-10-24 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Country Status (13)

Country Link
US (1) US20090111804A1 (es)
EP (1) EP2220053B1 (es)
JP (1) JP2011500833A (es)
CN (1) CN101835760A (es)
AR (1) AR069026A1 (es)
AT (1) ATE509012T1 (es)
AU (1) AU2008316821A1 (es)
CL (1) CL2008003184A1 (es)
PA (1) PA8801401A1 (es)
PE (1) PE20091345A1 (es)
TW (1) TW200934496A (es)
UY (1) UY31421A1 (es)
WO (1) WO2009055548A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
ES2170446T3 (es) * 1997-12-05 2002-08-01 Hoffmann La Roche Derivados de 1,3,8-triaza-espiro(4,5)decan-4-ona.
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
RS20060237A (en) * 2003-10-03 2008-11-28 Ortho-Mcneil Pharmaceutical Inc., Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Also Published As

Publication number Publication date
JP2011500833A (ja) 2011-01-06
AU2008316821A1 (en) 2009-04-30
AR069026A1 (es) 2009-12-23
TW200934496A (en) 2009-08-16
PA8801401A1 (es) 2009-05-15
UY31421A1 (es) 2009-04-30
CN101835760A (zh) 2010-09-15
WO2009055548A1 (en) 2009-04-30
EP2220053B1 (en) 2011-05-11
ATE509012T1 (de) 2011-05-15
EP2220053A1 (en) 2010-08-25
CL2008003184A1 (es) 2009-10-16
US20090111804A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
DOP2013000181A (es) Moduladores del receptor de glucagon
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
HN2010001563A (es) Compuestos
UY32996A (es) Antagonistas del receptor crth2 basados en indol
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
GT201400111A (es) Triazolopiridinas sustituidas
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
GT200700024A (es) Derivados de amina
GT200500309A (es) Derivados de sulfonilbencilimidazol
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
GT200500281A (es) Compuestos organicos.
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
CL2008003811A1 (es) Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor.
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2018001092A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.

Legal Events

Date Code Title Description
FD Application declared void or lapsed